Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
group_1_presentation_3_-_melanoma [2018/11/29 00:55] selvarak [Skin Colour] |
group_1_presentation_3_-_melanoma [2018/11/30 23:31] (current) choiy3 old revision restored (2018/11/30 21:09) |
||
|---|---|---|---|
| Line 19: | Line 19: | ||
| Fortunately, melanoma has one of the highest rates of survival, among any form of cancer, especially if it is caught early (Melanoma, n.d.). However, if the cancerous cells proliferate to other parts of the body and affect vital organs, it becomes very difficult to treat. If a patient is diagnosed quickly, and the melanoma is only in its early stages, the survival rate may be as high as 97% (“Survival Rates for Melanoma Skin Cancer”, 2018). However, on the other hand if the melanoma is diagnosed late, and is in its last stage, the survival rate is between 15% and 20% (“Survival Rates for Melanoma Skin Cancer”, 2018). However, each patient’s situation is different, and many factors may affect the survival rate such as the type of melanoma, as well as the tumor thickness. | Fortunately, melanoma has one of the highest rates of survival, among any form of cancer, especially if it is caught early (Melanoma, n.d.). However, if the cancerous cells proliferate to other parts of the body and affect vital organs, it becomes very difficult to treat. If a patient is diagnosed quickly, and the melanoma is only in its early stages, the survival rate may be as high as 97% (“Survival Rates for Melanoma Skin Cancer”, 2018). However, on the other hand if the melanoma is diagnosed late, and is in its last stage, the survival rate is between 15% and 20% (“Survival Rates for Melanoma Skin Cancer”, 2018). However, each patient’s situation is different, and many factors may affect the survival rate such as the type of melanoma, as well as the tumor thickness. | ||
| + | |||
| + | ==== Symptoms ==== | ||
| + | |||
| + | There are several symptoms that patients with melanoma may experience. These abnormalities include: non-healing sores, pigment in the form of redness or swelling that radiates from the original spot, itching, pain or tenderness, novel changes to an existing mole, and maybe even spots in the iris or blurring of vision (Swetter, 2018). | ||
| ======Etiology====== | ======Etiology====== | ||
| Line 87: | Line 91: | ||
| **Punch Biopsy** involves taking a small piece of skin in the shape of a circle (Melanoma Research Foundation, 2018). This procedure is fairly easy to do and involves administrating patients with local anesthesia meaning that the affected area is numbed. | **Punch Biopsy** involves taking a small piece of skin in the shape of a circle (Melanoma Research Foundation, 2018). This procedure is fairly easy to do and involves administrating patients with local anesthesia meaning that the affected area is numbed. | ||
| + | |||
| + | ====== Pathophysiology ====== | ||
| + | |||
| + | Mutations that occur in the DNA greatly alter cellular functions. Specifically, the cellular rates of proliferation and differentiation become uncontrolled and increased. The mutations to DNA also cause the cell to often ignore apoptosis or rather programmed cell death. They also make the skin and cells more susceptible to the harmful and cancer-causing potential of UV radiation (Swetter, 2018). Interestingly, higher number of birth marks or spots (nevus counts) on the body are a predisposing factor for the disease (Swetter, 2018). This is however a strong correlation and causation has not been established. | ||
| + | |||
| + | The specific mutations are frequently in the BRAF, NRAS and KIT oncogenes. Mutations in oncogenes increase the risk of cancer and these three in particular have been linked with melanoma. Sun exposed areas usually have mutations in the BRAF oncogene whereas areas which aren’t exposed to the sun as much show mutations in the KIT oncogene (Takata, 2010). Some other mutations have also been discovered which lead to disruptions to the p16/Rb pathway, cyclin D1 (CCND1) and cyclin dependent kinase 4 (CDK4) which all alter cell cycle progression and cellular senescence (Sauter, 2002; Takata 2010). Proliferation and telomerase mutations also play a role in speeding up the progression of melanoma (Murata, 2007). | ||
| + | |||
| + | ===== Stages of Skin Cancer ===== | ||
| + | |||
| + | **Stage 0** - at this stage melanoma is in situ, meaning that the melanoma cells are only found in the outer layer of the epidermis. In this stage, it is unlikely for melanoma to spread to other parts of the body. | ||
| + | |||
| + | **Stage I** - This is the primary melanoma stage, where melanoma cells are only found in the skin. | ||
| + | - Stage IB - subgroup of stage I, depending on the thickness of melanoma and whether or not the pathologist is able to see ulceration under a microscope. | ||
| + | |||
| + | **Stage II** - Melanoma is thicker than in stage I, and extends through the epidermis into the dermis (the inner layer of the skin). In this stage, there is a higher chance of spreading. The stage can be divided into 3 subgroups -- A, B, or C-- depending on the thickness of melanoma and whether there is ulceration. | ||
| + | |||
| + | **Stage III** - In this stage, melanoma has spread locally or through the lymphatic system, which is a part of the immune system and drains fluid from the body through tubes or vessels. This stage is also divided into subgroups -- A,B,C or D -- depending on size and number of lymph nodes impacted by melanoma, whether primary tumour has satellite lesion and if ulceration appears under a microscope or not. | ||
| + | |||
| + | **Stage IV** - Melanoma has spread through the bloodstream to other parts of the body (distant locations on the skin, distant lymph nodes or other organs). | ||
| + | |||
| + | - M1a: the cancer only spread to distant skin. | ||
| + | |||
| + | - M1b: the cancer spread to the lung. | ||
| + | |||
| + | - M1c: the cancer spread to any other location that does not involve central nervous system. | ||
| + | |||
| + | - M1d: The cancer has spread to the central nervous system (brain, spinal cord or cerebrospinal fluid). | ||
| + | |||
| + | ====== Current Treatments, Future Treatments and Implications ====== | ||
| + | === Chemotherapy === | ||
| + | |||
| + | __Vindesine__ - The vinca alkaloid vindesine has also been evaluated in the adjuvant treatment of malignant melanoma. In a non-randomised trial, researchers have found a highly significant improvement in disease-free as well as the overall survival in patients treated with vindesine following resection of regional lymph nodes compared with patients followed by observation alone. | ||
| + | |||
| + | __Levamisole__ - This is another type of chemotherapy that has been evaluated as an adjuvant treatment following excision of a primary melanoma. In a trial conducted by the National Cancer Institute of Canada, were able to demonstrate a reduction of 29% in both the death rate (p = 0.08) and the recurrence rate (p = 0.09) in a cohort of patients who were randomized to receive adjuvant levamisole as opposed to observation alone. | ||
| + | |||
| + | === Gene Therapy === | ||
| + | |||
| + | Constitutive activation of certain signal transducer and activator of transcription proteins, including Stat3, has been found in increasing numbers of human cancers. Researchers have found that the levels of activated Stat3 in the B16 tumour cell line are relatively low. Over-expression of a Stat3 Dominant-negative Protein, Stat3b, Induces Cell Death in B16 Tumour Cells in Vitro (Niu et al., 1999). | ||
| + | |||
| + | |||
| ====== References ====== | ====== References ====== | ||
| Line 106: | Line 150: | ||
| Melanoma Research Foundation. (2017, June 26). Diagnosing Melanoma. Retrieved November 27, 2018, from | Melanoma Research Foundation. (2017, June 26). Diagnosing Melanoma. Retrieved November 27, 2018, from | ||
| https://www.melanoma.org/understand-melanoma/diagnosing-melanoma | https://www.melanoma.org/understand-melanoma/diagnosing-melanoma | ||
| - | |||
| Metastatic Melanoma. (2018). Melanoma Research Foundation. Retrieved from https://www.melanoma.org/understand-melanoma/what-is-melanoma/metastatic-melanoma | Metastatic Melanoma. (2018). Melanoma Research Foundation. Retrieved from https://www.melanoma.org/understand-melanoma/what-is-melanoma/metastatic-melanoma | ||
| + | |||
| + | Murata, H., Ashida, A., Takata, M., Yamaura, M., Bastian, B. C., & Saida, T. (2007). Establishment of a novel melanoma cell line SMYM‐PRGP showing cytogenetic and biological characteristics of the radial growth phase of acral melanomas. Cancer science, 98(7), 958-963. | ||
| + | |||
| + | Sauter, E. R., Yeo, U. C., von Stemm, A., Zhu, W., Litwin, S., Tichansky, D. S., ... & Bastian, B. C. (2002). Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer research, 62(11), 3200-3206. | ||
| Skin Cancer, Melanoma. (n.d.). Health Link BC. Retrieved from https://www.healthlinkbc.ca/health-topics/hw206547 | Skin Cancer, Melanoma. (n.d.). Health Link BC. Retrieved from https://www.healthlinkbc.ca/health-topics/hw206547 | ||
| Line 117: | Line 164: | ||
| Survival Rates for Melanoma Skin Cancer. (2018). American Cancer Society. Retrieved from | Survival Rates for Melanoma Skin Cancer. (2018). American Cancer Society. Retrieved from | ||
| https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html | https://www.cancer.org/cancer/melanoma-skin-cancer/detection-diagnosis-staging/survival-rates-for-melanoma-skin-cancer-by-stage.html | ||
| + | |||
| + | Swetter, S. M. (2018, October 31). Cutaneous Melanoma. Retrieved from https://emedicine.medscape.com/article/1100753-overview#a5 | ||
| Takata, M., Murata, H., & Saida, T. (2010). Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment cell & melanoma research, 23(1), 64-71. | Takata, M., Murata, H., & Saida, T. (2010). Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment cell & melanoma research, 23(1), 64-71. | ||
